comprising 23 hospitals of Taiwan. A total of 12,770 CHC patients receiving PR therapy for at least 4 weeks between January 2003 and December 2015 were enrolled and their data were linked to the Taiwan National Health Insurance Research Database for studying the development of 10 autoimmune diseases. The mean follow-up duration was 5.3 ± 2.9 years with a total of 67,930 person-years, and the annual incidence of systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) was 0.03%. Other autoimmune diseases were not assessable due to few events. Body mass index ≥24 kg/m 2 was an independent predictor of the low incidence of SLE or RA (hazard ratio 0.40, 95% confidence interval 0.17-0.93, p = 0.034). A sustained virological response (SVR) to PR therapy was not associated with the low incidence of SLE or RA in any subgroup analysis. CHC patients achieving SVR to PR therapy did not exhibit an impact on the incidence of SLE or RA compared with non-SVR patients.
Chronic hepatitis C (CHC) is well known for its hepatitis C virus (HCV)-associated systemic diseases with extrahepatic manifestations (EMs), such as diabetes mellitus (DM), mixed cryoglobulinemia (MC), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren's syndrome (SS), and porphyria cutanea tarda 1 . MC vasculitis increases HCV-related morbidity and mortality 2 . Approximately 40-74% of CHC patients experience immunological complications during the course of the disease 2 . The awareness of these immunological complications of HCV infection facilitates hepatologists to diagnose these patients early 3 . On the other hand, patients with rheumatic diseases are often tested for HCV infection 1 .
A previous Taiwan National Health Insurance Research Database (NHIRD) study reported that antiviral treatment with pegylated interferon plus ribavirin (PR) does not decrease the incidence of catastrophic autoimmune diseases 4 , but the effects of baseline characteristics, virological profiles, and therapeutic outcome on autoimmune diseases are unknown. Although direct-acting antiviral agents (DAAs) are the standard of care for CHC 6, 6 , the data of the effect of a sustained virological response (SVR) to PR therapy on the incidence of autoimmune diseases provide valuable information for physicians.
We conducted this nationwide cohort study to elucidate the effects of baseline factors and therapeutic outcome of PR therapy on the incidence of autoimmune diseases in CHC patients.
Results
Baseline characteristics of the study population. A total of 15,836 patients were enrolled initially.
Among them, 934 and 2,042 patients were excluded because of hepatitis B virus (HBV) coinfection and unavailable SVR status, respectively (2 patients had both); 29 patients were excluded because of death during or within 6 months of PR therapy, and 63 patients were excluded because of SLE or RA development before PR therapy. Finally, 12,770 patients (9,725 patients with SVR and 3,045 patients without SVR) were analyzed ( Fig. 1 ).
The mean age was 54.6 ± 11.4 years, and 5,954 (46.6%) patients were men. The mean body mass index (BMI) was 25.0 ± 3.5 kg/m 2 . The baseline mean aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were 91.1 ± 64.4 and 137.4 ± 110.3 U/L, respectively. The mean platelet count was 174.7 ± 54.0 × 10 9 /L, and mean FIB-4 was 2.9 ± 2.5. Furthermore, 1,969 (18.5%) patients had liver cirrhosis (LC), and 1,269 (18.2%) and 1,411 (20.3%) patients had DM and hypertension, respectively. In total, 6,052 (47.4%), 5,811 (45.5%), and 907 (7.1%) patients were diagnosed with HCV genotypes 1, 2, and non-1/2, respectively, and the median HCV RNA level was 5.7 ± 1.0 log 10 IU/mL. The mean PR therapy time was 7.1 ± 2.9 months. The mean follow-up duration was 5.3 ± 2.9 years with a total of 67,930 person-years. The SVR rate at 24 weeks after PR therapy was 76.2%. The annual incidence of SLE or RA was 0.03% (Table 1 ).
Cumulative incidence rate of SLE or RA. The mean age of the patients who achieved SVR to PR therapy (SVR group) was 53.9 ± 11.5 years and of those who did not achieve SVR (non-SVR group) was 56.8 ± 10.7 years (p < 0.001). The median follow-up periods for the SVR and non-SVR groups were 5.4 ± 3.0 and 5.0 ± 2.8 years (p < 0.001), respectively. The SVR group exhibited lower BMI, HCV RNA levels, and FIB-4 index; lower proportion of LC; higher platelet count, and AST and ALT levels; shorter PR therapy time; and higher rate of rapid virological response. The SVR group exhibited a higher proportion of HCV genotype 2 infection than did the non-SVR group (50.8% vs 28.6%, p < 0.001). The SVR group exhibited a lower rate of death before developing autoimmune diseases or last visit than did the non-SVR group (3.43% vs 10.48%, p = 0.013). In the non-SVR group, 43.0, 5.0, and 52.0% of patients had a decline in HCV RNA of ≤2 log 10 IU/mL (null response), a decline in HCV RNA of >2 log 10 IU/mL but with detectable HCV RNA (partial virological response), and undetectable HCV RNA at the end of PR therapy (relapse), respectively.
The annual incidence of SLE, RA, and SLE or RA did not differ between the SVR and non-SVR groups (0.006% vs. 0.013%, p = 0.343; 0.023% vs. 0.026%, p = 1.000; 0.03% vs 0.04%, p = 0.799) ( Table 1 ). The 10-year cumulative incidence rates of SLE or RA, estimated using the modified Kaplan-Meier method and Gray's method, were 0.34% (95% confidence interval [CI] 0.17-0.62) for the SVR group and 0.71% (95% CI 0.23-1.75) for the non-SVR group (p = 0.580) ( Fig. 2 ). Table 2 shows the multivariate Cox proportional hazard analysis for determining the independent predictors of the SLE or RA. The non-SVR group did not exhibit an increased risk for SLE or RA compared with the SVR group (Hazard ratio [HR] 1.32, 95% CI 0.50-3.51; p = 0.580) after adjustment for age, sex, and competing mortality ( Fig. 2 ). Few patients with hypertension or an estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73m 2 exhibited SLE or RA (<3 events); therefore, these two factors were not listed for comparison. BMI ≥ 24 kg/m 2 was an independent www.nature.com/scientificreports www.nature.com/scientificreports/ predictor of the low incidence of SLE or RA (HR 0.40, 95% CI 0.17-0.93, p = 0.034) after adjustment for competing risk. Other factors, such as age, ALT levels, HCV RNA levels, and LC, did not exhibit significant differences. Table 3 presents the effect of SVR on the incidence of SLE or RA in different subgroups. SVR to PR therapy was not associated with the low incidence of SLE or RA in any subgroup analysis, stratified by age, sex, BMI, AST and ALT levels, eGFR, HCV RNA levels, HCV genotype, FIB-4 index, DM, hypertension, and LC (all p > 0.05).
Relative risks of SLE or RA after adjustment for competing mortality.

Effect of SVR on the incidence of SLE or RA in different subgroups.
Discussion
In this multicenter retrospective study, we observed that SVR to PR therapy does not decrease the incidence of SLE or RA in CHC patients. BMI ≥ 24 kg/m 2 was the only independent predictor of the low incidence of SLE or RA.
Taiwanese Chronic Hepatitis C Cohort (T-COACH) is a nationwide HCV registry consortium that includes 23 regional hospitals and medical centers of Taiwan from January 2003 to December 2015, and T-COACH accounted for 21% of the treated CHC population of Taiwan over the 13-year period. In addition to International Classification of Disease, ninth revision, Clinical Modification (ICD-9-CM), T-COACH included baseline characteristics, virological profiles, and therapeutic outcomes. In this study, we enrolled 12,770 patients (9,725 patients with SVR and 3,045 patients without SVR) for comparison and clarified baseline variables associated with the incidence of SLE or RA. We found that BMI ≥24 kg/m 2 was the only predictor of the low incidence of SLE or RA. This multicenter study reflected daily practice in the real world, and SVR to PR was not associated with the low incidence of SLE or RA in any subgroup analysis after adjustment for age, sex, and competing mortality.
Arthralgia is a common EM of HCV infection, and its prevalence is estimated up to 23% 2,7 . HCV-related arthritis could be polyarthritis involving small joints and intermittent mono-oligo-articular nondestructive arthritis involving large and medium joints, and the patterns of HCV-related arthritis are similar to those of mild RA presenting with polyarthritis 8 . The rheumatoid factor was identified in 50-80% of CHC patients 9 . The pathogenesis may be the direct invasion of synovial cells by HCV or a cytokine-induced disease 10 . Epidemiological studies have shown that the prevalence of HCV infection is significantly higher (10-11%) in SLE patients Figure 2 . Cumulative incidence of SLE or RA in SVR and non-SVR groups determined using the modified logrank test after adjustment for age, sex, and competing mortality. SVR patients achieved a sustained virological response (SVR) to pegylated interferon plus ribavirin (PR) therapy; non-SVR patients did not achieve SVR to PR therapy. www.nature.com/scientificreports www.nature.com/scientificreports/ compared to the control group (1.0-1.3%) 11, 12 , which suggests a potential interaction between HCV infection and SLE. Patients with SLE and CHC share many common immunological features, such as hypocomplementemia and the presence of antinuclear and anticardiolipin antibodies 13 . HCV does not have a DNA intermediate in its life cycle, and HCV RNA cannot integrate into the human genome. HCV may act as a chronic stimulus to the immune system 14, 15 . The HCV envelope protein E2 can bind the CD81 molecule on the cell membrane of both hepatocytes and B-cells, and the binding on the B-cells may lower the threshold for the activation of B-cells 16, 17 .
Variable HR (95% CI) p value
Hsu et al. reported that PR therapy does not decrease the incidence of catastrophic autoimmune disease 4 , and the present study revealed that SVR to PR does not decrease the incidence of SLE or RA. In this study, the observed incidence of SLE or RA was 21 per 67,930 person-years, which is similar to the incidence of 24.4 per 100,000 person-years (7.2, 95% CI: 6.5-8.0 in SLE; 17.2, 95% CI: 16.1-18.4 in RA) between 2005 and 2009 in Taiwan 18 . Why HCV eradication did not decrease the incidence of SLE or RA is yet to be studied, particularly in terms of immunological profiles before versus after HCV eradication.
The effect of BMI on the incidence of SLE or RA in CHC patients is still unknown. Escalante et al. showed that underweight patients with RA had higher mortality, which may be related to systemic inflammation 19 . SLE is a chronic inflammatory connective tissue disorder characterized by elevated proinflammatory cytokines in the blood, including leptin. Li et al. revealed that Asian SLE patients ≥ 40 years with a BMI < 25 had higher leptin 20 . We speculate that thinner HCV patients had higher systemic inflammatory cytokine levels, such as leptin, and the combination of systemic inflammatory cytokines and HCV may trigger SLE or RA in CHC patients.
MC is the most well-known EM in CHC patients, and 19-54% of CHC patients exhibit MC 21, 22 . A systematic review revealed that the prevalence of MC vasculitis was 4.9% in CHC patients compared with 0% in non-HCV healthy people 22 . However, cryoglobulin measurement is not a routine practice in Taiwan due to the policy of Taiwan National Health Insurance and is usually not performed before SLE or RA diagnosis. Consequently, the events of MC were less than three in this study. SS is a systemic autoimmune disease (SAD) associated with HCV infection 23 and has been diagnosed in 10-30% of CHC patients 22, 24 . Due to less than three events, SS was not assessable in this cohort.
This study has several limitations. First, the events of several autoimmune diseases, including MC, chronic glomerulonephritis, autoimmune thyroiditis, lichen planus, SS, immune thrombocytopenic purpura, autoimmune hemolytic anemia, and porphyria cutanea tarda, were less than three; hence, these autoimmune diseases were not assessable. However, See et al. reported a low incidence of SS (11.8, 95% CI: 10.8-12.7) in Taiwan 18 , but the nationwide incidence of cryoglobulinemia was unknown. Second, we collected baseline virological features, complete blood count, and biochemical data, but the effect of baseline autoantibody profiles and their temporal 
